Digestive DisordersMar 15, 2026
About 60% of adults with lymphocytic colitis experience a single episode that resolves on its own. That's a striking number for a condition that can cause weeks or months of relentless watery diarrhea, urgency, and real disruption to daily life. But here's the catch: because the colon looks perfectly normal during a standard colonoscopy, many people cycle through appointments and tests before anyone thinks to take a biopsy. Without that biopsy, lymphocytic colitis is invisible.
Lymphocytic colitis (LC) is a form of microscopic colitis, meaning the inflammation only shows up under a microscope. It typically strikes middle-aged to older adults, with a median age around 59 to 67 years, and is more common in women. The hallmark is chronic, watery, non-bloody diarrhea, often accompanied by abdominal pain, weight loss, and sometimes fecal incontinence. It can significantly affect quality of life even though it carries a largely benign prognosis.
ColonoscopyMar 15, 2026
Most people assume colonoscopy prep means days of dietary misery. The research tells a different story. For generally healthy, average-risk outpatients using a modern split-dose bowel prep, prospective data show no association between what you eat 2 to 3 days before the procedure and how clean your bowel ends up being.
That means the restrictive eating many people dread can usually be compressed into a single day, not two or three. Several randomized trials and meta-analyses back this up: extending a low-residue or low-fiber diet beyond one day before the colonoscopy does not improve prep quality. It just makes the whole process harder to follow.
InfectionsMar 15, 2026
C. diff is unquestionably contagious. It spreads through a fecal-oral route, meaning spores from an infected person's stool end up on hands, surfaces, or objects, and someone else swallows them. What makes C. diff particularly stubborn is that its spores can survive on surfaces for months, turning rooms, toilets, and shared equipment into lasting reservoirs of infection.
But the part most people miss: you don't have to be visibly sick to spread it. A significant number of people carry toxigenic C. diff without any symptoms at all. These asymptomatic carriers shed spores and contaminate their surroundings, acting as silent sources of ongoing transmission in hospitals, long-term care facilities, and homes.
CancerMar 15, 2026
CA 19-9 is the most validated blood marker for pancreatic cancer, yet it catches only about 72–80% of symptomatic cases and flags plenty of people who don't have cancer at all. It's a genuinely useful tool in the right context, but it's also widely misunderstood. If your doctor ordered this test, or if a result came back high (or suspiciously normal), understanding what CA 19-9 can and can't tell you matters more than the number on the page.
Ulcerative ColitisMar 15, 2026
About one in four people diagnosed with limited ulcerative colitis will see their disease creep upward to involve the entire colon within a decade. That progression, called pancolitis, isn't just a change in geography. It marks a shift toward higher relapse rates, more hospitalizations, greater odds of surgery, and an elevated risk of colorectal cancer. If you or someone you care about has UC, understanding what pancolitis means practically is worth the time.
Pancolitis refers to continuous inflammation stretching from the rectum all the way through the proximal (upper) colon. It affects roughly 20 to 40% of people with UC, making it the most extensive form of the disease. And while the name sounds dramatic, what really matters is how it changes the playbook for monitoring, treatment, and long-term risk.
Cancer ScreeningMar 15, 2026
Cologuard detects about 92% of colorectal cancers from a stool sample you collect at home. That's genuinely impressive. But here's the critical distinction most people miss: catching cancer is not the same as preventing it. Colonoscopy can find precancerous polyps and remove them during the same procedure, stopping cancer before it starts. Cologuard can flag some of those polyps but can't do anything about them, and it misses a substantial number of the advanced ones colonoscopy would catch.
Both tests are guideline-endorsed options for average-risk adults. The choice between them isn't about one being "good" and the other "bad." It's about understanding what each test actually does, what it misses, and what happens after you get a result.
Irritable Bowel SyndromeMar 15, 2026
Most drugs for irritable bowel syndrome with constipation (IBS-C) get absorbed into your bloodstream and work from the inside out. Ibsrela (tenapanor) takes the opposite approach. It acts almost entirely within the gut itself, with very low absorption into the body. That local-only design is central to both how it works and why its safety profile looks the way it does.
FDA-approved in 2019, Ibsrela at 50 mg twice daily improved both constipation and abdominal pain in trials involving more than 1,200 adults. The trade-off is straightforward: diarrhea is the most common side effect, but it tends to be mild to moderate and shows up early rather than building over time.
Digestive DisordersMar 15, 2026
Diverticulitis doesn't produce a single, recognizable stool appearance. If you're scanning the toilet bowl looking for a visual clue that confirms a diagnosis, research simply doesn't support that approach. What the evidence does show is that diverticular disease changes how often you go, how loose your stool is, and how long those shifts can linger, sometimes for months after an acute episode resolves.
That distinction matters more than it sounds. Complications like perforation, abscess, or fistula are diagnosed with CT imaging, not by looking at stool. So the real value isn't in identifying a specific appearance. It's in recognizing when your bowel habits have shifted in a way that deserves attention.
Digestive DisordersMar 15, 2026
Nearly every gallbladder condition, from common gallstones to rare torsion, produces the same core sensation: steady, moderate to severe pain in the upper right abdomen or upper middle abdomen (epigastrium) that lasts at least 30 minutes and often sends people to the doctor. That consistency is useful because it tells you where to focus your attention. But it also means the details surrounding that pain, like fever, timing, and how fast things escalate, are what actually separate a nuisance from an emergency.
The pain isn't sharp and fleeting. It doesn't come and go in quick waves. Biliary pain is steady, often radiates to the back or right shoulder, and tends to interrupt whatever you're doing. If that description sounds familiar, keep reading.
Liver HealthMar 15, 2026
Liver pain doesn't always stay in one spot. The research shows it typically lands in the right upper abdomen, just under the rib cage, but it can also show up in your upper back, right shoulder, or even your legs. That wandering quality is exactly what makes it confusing, and why so many people aren't sure whether their liver is actually the source.
The liver itself doesn't have the same kind of pain-sensing nerves your skin does. Instead, the pain you feel comes largely from the capsule surrounding the liver and nearby structures. When that capsule stretches or becomes inflamed, the result is usually a dull, pressure-like ache or a sense of heaviness rather than a sharp, stabbing sensation.
AntibioticsMar 15, 2026
Fidaxomicin and vancomycin clear a C. difficile infection at roughly the same rate. Where fidaxomicin pulls ahead, and it's not subtle, is in what happens next: significantly fewer people relapse. If you've dealt with C. diff before, or if you're facing treatment decisions right now, that distinction between "cured" and "cured and staying that way" is the whole ballgame.
Fidaxomicin is a narrow-spectrum macrolide antibiotic taken by mouth. It barely gets absorbed into the bloodstream, which means it concentrates where C. diff actually lives: your gut. And because it's narrow-spectrum, it does far less collateral damage to your normal gut bacteria than older treatments. That preservation of your microbiome appears to be a big part of why recurrence rates drop.
Gastrointestinal HealthMar 15, 2026
The gallbladder is often treated as disposable, a small pouch you can live without. But it plays a surprisingly active role in digestion, bile acid regulation, and even broader metabolic health. It stores and concentrates bile, releases it precisely when you need it, shields your organs from toxic bile acids, and influences signaling pathways tied to glucose and lipid metabolism.
Think of it less as a passive storage bag and more as a timing and quality-control system for one of your body's most important digestive fluids.
CancerMar 15, 2026
No study has reported a cancer risk signal for psyllium husk. Not in humans, not in animals, not in lab work. If you've been searching for a psyllium husk cancer warning, the research simply doesn't contain one. What it does contain is a growing body of experimental evidence suggesting psyllium may actually work against cancer, particularly in the colon. The real safety concerns are decidedly less dramatic, but still worth paying attention to.
That disconnect between fear and evidence is worth unpacking, because the actual risks of psyllium husk are the ones most people never think to ask about.
Gastrointestinal HealthMar 15, 2026
A small clinical trial found no extra symptom benefit when lactose-intolerant adults ate lactose-free yogurt compared to regular yogurt, as long as both contained high levels of live cultures. That finding reframes the entire conversation. Regular yogurt is already naturally lower in lactose than milk, and its bacteria actively help break down whatever lactose remains.
That doesn't make lactose-free yogurt pointless. It does mean the decision is more nuanced than "I'm lactose intolerant, so I need the lactose-free version." Here's what the research actually supports.
BiomarkersMar 15, 2026
A normal fecal calprotectin result has excellent negative predictive value for ruling out inflammatory bowel disease. In practical terms, that means if your doctor suspects your chronic gut symptoms might be IBD but your fecal calprotectin comes back normal, you may be able to skip the colonoscopy entirely. For the millions of people living with unexplained abdominal pain, bloating, and altered bowel habits, that distinction between "inflamed gut" and "irritated gut" is one of the most consequential calls in gastroenterology.
Fecal calprotectin isn't a new or experimental test. It's a well-validated, non-invasive biomarker that has become a cornerstone tool for differentiating functional bowel disorders like irritable bowel syndrome from true inflammatory disease, and for tracking IBD once diagnosed. But like any test, it has blind spots worth understanding before you see your results.
Urinary HealthMar 15, 2026
Alkaline urine can inflate your urobilinogen result from roughly 30% of the filtered load to over 100%, without any change in what's actually circulating in your blood. That single fact should make you think twice before reading too much into a urobilinogen value on a routine urinalysis. The number on the strip reflects a tangle of variables: how much bilirubin your body produces, which bacteria live in your gut, when during the day you collected the sample, and the pH of your urine at that moment.
Urobilinogen is a colorless compound your gut bacteria make by breaking down bilirubin, the waste product of old red blood cells. A small amount normally shows up in urine. But "normal" is doing a lot of heavy lifting here, because what actually lands in the cup depends on a chain of biological steps, each with its own set of disruptors.
Gastrointestinal HealthMar 15, 2026
When researchers spiked stool samples with known pathogens and ran them through the Diagnostic Solutions GI-MAP assay, the test correctly detected what was there about 80% of the time. That sounds decent until you see the other number: specificity landed at just 26 to 27%. That means for every sample where a pathogen was genuinely absent, the GI-MAP test still reported a positive result roughly three out of four times. Those aren't rounding errors. Those are false positives that could lead directly to antimicrobial prescriptions you never needed.
The GI-MAP is one of the most popular stool tests in functional medicine, used to profile gut bacteria, flag pathogens, and paint a picture of your microbiome. But popularity and accuracy aren't the same thing, and the independent data on this specific test tell a story worth understanding before you hand over your credit card or start a treatment protocol based on the results.
Liver HealthMar 15, 2026
End-stage liver disease doesn't announce itself with one unmistakable symptom. It shows up as a combination of serious problems that accumulate as the liver loses its ability to function. The tricky part is that severe liver damage develops gradually and the individual symptoms aren't specific, meaning each one on its own could point to something else entirely. It's the pattern that matters.
That pattern typically includes jaundice, fluid build-up, confusion or personality changes, bleeding problems, extreme fatigue, breathing difficulty, and a handful of other late-stage signs. If several of these appear together, treat them as a medical emergency, not a puzzle to solve on your own.
Digestive DisordersMar 15, 2026
Psyllium, the single ingredient in Metamucil, has clinical trial evidence behind four distinct health outcomes: relieving constipation, lowering LDL cholesterol, improving blood sugar control in type 2 diabetes, and supporting modest weight loss. That makes it one of the best-studied fiber supplements you can buy.
The catch is that these results consistently require around 10 grams per day or more, taken for at least several weeks. A single spoonful on a random Tuesday morning probably isn't doing much.
DiabetesMar 15, 2026
Retatrutide delivers some of the highest weight loss numbers seen in obesity drug trials, but that potency comes at a cost. Network meta-analyses comparing it against other GLP-1 and dual agonist drugs consistently rank retatrutide among the highest for overall adverse events, particularly gastrointestinal ones. The side effects are common, overwhelmingly gut-related, and clearly dose-dependent. Most are mild to moderate. But "common and mild" still matters when you're the one experiencing weeks of nausea during dose escalation.
Here's what the phase 2 trial data actually reveals about what taking this drug feels like, what's manageable, and what signals deserve closer attention.
